Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours

Annals of Oncology

Volumn 16, Issue 12, 2005, Pages 1915-1920

  Maroto, P ^a,b   Garcia del Muro X ^a   Aparicio, J ^a   Paz Ares, L ^a   Arranz, J A ^a   Guma, J ^a   Terrassa, J ^a   Barnadas, J ^a   Dorta, J ^a   Germa Lluch J R ^a  

^a The Spanish Germinal Group   (Spain)

^b Hospital Sant Pau   (Spain)

Author keywords

Non seminomatous germ cell tumours; Risk adapted surveillance; Stage I

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; DRUG FATALITY; DRUG HYPERSENSITIVITY; EMBRYONAL CARCINOMA; FEASIBILITY STUDY; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OUTPATIENT; PATERNITY; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARCINOMA, EMBRYONAL; CHEMOTHERAPY, ADJUVANT; CHORIOCARCINOMA; ETOPOSIDE; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PROGNOSIS; RISK MANAGEMENT; SEMINOMA; SURVIVAL RATE; TERATOMA; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 28444485983     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi397     Document Type: Article

References (24)

1. Weissbach L, Hartlapp JH. Adjuvant chemotherapy of metastatic stage I nonseminomatous testis tumor. J Urol 1991; 143: 1295-1298.
2. Williams SD, Stablein DM, Einhorn LH. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987; 317: 1433-1438.
3. Read G, Stenning SP, Cullen NH et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992; 10: 1762-1768.
4. Klepp O, Olsson AM, Henrikson H et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis. Multivariate analysis of a prospective multicenter study. J Clin Oncol 1990; 8: 509-518.
5. Horwich A, Cullen MH, Stenning SP. Primary chemotherapy after orchidectomy for stage I and II nonseminoma. Semin Oncol 1998; 25: 154-159.
6. Pont J, Albrecht W, Postner G et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: Long-term results of a prospective trial. J Clin Oncol 1996; 14: 441-448.
7. Dearnaley DP, Fossa SD, Kaye SB et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for clinical stage I nonseminomatous germ cell tumors: A Medical Research Council Pilot Study. Proc Am Soc Clin Oncol 1998; 17: 309 (Abstr).
8. Cullen MH, Stenning SP, Parkinson MC et al. Short course adjuvant chemotherapy in high risk nonseminomatous germ cell tumors of the testis: A Medical Research Council report. J Clin Oncol 1996; 14: 1106-1111.
9. Sharir S, Jewett MA, Sturgeon JFG et al. Progression detection of stage I nonseminomatous testis cancer on surveillance: Implications for the follow-up protocol. J Urol 1999; 161: 472-475.
10. Sogani PC, Perrotti M, Herr HW et al. Clinical stage I testis cancer: Long-term outcome of patients on surveillance. J Urol 1998; 159: 855-858.
11. Chevreau C, Mazerolles C, Soulie M et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 2004; 46: 209-214.
12. Vergouwe Y, Steyerberg EW, Eijkemans MJ et al. Predictors of occult metastasis in clinical stage I nonseminoma: A systematic review. J Clin Oncol 2003; 21: 4092-4099.
13. Germà-Lluch JR, Climent MA, Villavicencio H et al. Treatment of stage I testicular tumors. Br J Urol 1993; 71: 473-477.
14. Germa-Lluch JR, Garcia del Muro X, Maroto P et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: The experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002; 42: 553-562.
15. Garcia del Muro X, Maroto P, Barnadas A et al. Long-term results following one course of adjuvant chemotherapy for high-risk stage I non-seminomatous germ cell tumors: The Spanish Germ Cell Cancer Group experience. Oncologica 1997; 14: 25.
16. McLeod DG, Weiss RB, Stablein DM et al. Staging relationships and outcome in early stage testicular cancer: A report from the testicular cancer intergroup study. J Urol 1991; 145: 1178.
17. Moynihan C. Testicular cancer: The psychosocial problems of patients and their relatives. Cancer Surv 1987; 6: 477-510.
18. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 1994; 54: 362.
19. Freedman LS, Parkinson MC, Jones WG et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987; 11: 294-298.
20. Albers P, Siener R, Kliesch S et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: Results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003; 15: 1505-1512.
21. Pedersen-Bjergaard J, Daugaard G, Hansen SW et al. Increased risk of myelodysplasia for germ cell tumours. Lancet 1991; 338: 359-363.
22. Faulkner K, Moores BM. Radiation dose and somatic risk from computed tomography. Acta Radiol 1987; 28: 483.
23. Spermon JR, Roeleveld TA, van der Poel HG et al. Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors. Urology 2002; 59: 923-929.
24. Thijssens K, Vaneerdeweg W, Schrijvers D et al. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer. Acta Chir Belg 2003; 103: 599-602.